Grant: Engage Grants Program
University of Victoria
$25,000.00
Cloning and expression of human glucocerebrosidase
EF 2014-15
Résumé
Parkinson's disease (PD) is a worldwide health problem that is characterized by the buildup of abnormalprotein deposits in the brain, loss of neurons, and behavioural symptoms. Mutations in the enzymeglucocerebrosidase (GBA1) are the most common genetic risk factor for development of PD. Numerousstudies have noted a correlation between reduced GBA1 activity and increased levels of abnormal proteindeposits in the brain, but the relationship remains poorly understood. The collaboration between AlectosTherapeutics and the Boulanger group at the University of Victoria aims to develop and optimize methods forproducing glucocerebrosidase. These methods will be used to produce protein to support basic biochemicalstudies to clarify the relationship between GBA1 and PD. The success of this project may lead to a betterunderstanding of GBA1 properties and mechanism and could ultimately result in new strategies to developtherapies for Parkinson's disease.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
470141-2014
Name nom
Boulanger, Martin
Department département
Biochemistry and Microbiology
Organization id
7
Institution établissement
University of Victoria
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2014
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5404
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Enzymes
Research subject fr
Enzymes
Partie
1
Nb partie
1
Application title
Cloning and expression of human glucocerebrosidase
Keyword
NSERC
Application summary
Parkinson's disease (PD) is a worldwide health problem that is characterized by the buildup of abnormalprotein deposits in the brain, loss of neurons, and behavioural symptoms. Mutations in the enzymeglucocerebrosidase (GBA1) are the most common genetic risk factor for development of PD. Numerousstudies have noted a correlation between reduced GBA1 activity and increased levels of abnormal proteindeposits in the brain, but the relationship remains poorly understood. The collaboration between AlectosTherapeutics and the Boulanger group at the University of Victoria aims to develop and optimize methods forproducing glucocerebrosidase. These methods will be used to produce protein to support basic biochemicalstudies to clarify the relationship between GBA1 and PD. The success of this project may lead to a betterunderstanding of GBA1 properties and mechanism and could ultimately result in new strategies to developtherapies for Parkinson's disease.